In this context, we have investigated the therapeutic potential of the DHODH inhibitor TFN, an approved drug for the treatment of RRMS [19,20], on both neuronal and mitochondrial protection. The gene discussed is DHODH; the disease is relapsing-remitting multiple sclerosis.